{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-26-000054","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2026-07-09T21:10:23+00:00","discovered_at":"2026-07-09T21:12:00.249534+00:00","generated_at":"2026-07-09T21:12:04.594473+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Travere Therapeutics CAO Sandra Calvin to retire; John Torell to succeed","bullets":["Sandra Calvin to retire as CAO/PAO after filing 10-K expected in February 2027.","John Torell, current VP Controller, to be appointed CAO/PAO before retirement date.","Torell joined Travere in 2021; previously VP Controller at Pacific Life and audit manager at Deloitte.","Torell holds CFA and CPA designations; transition plan aims for orderly handover."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-26-000054","json":"https://secwatch.observer/filing/0001438533-26-000054.json","markdown":"https://secwatch.observer/filing/0001438533-26-000054.md","text":"https://secwatch.observer/filing/0001438533-26-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000054/0001438533-26-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000054/tvtx-20260706.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-09T21:12:04.594473+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}